Samsung Biologics posts strong Q1 2025 results, launches new facilities

SOUTH KOREA – Samsung Biologics, a global leader in contract development and manufacturing (CDMO), has announced solid financial results for the first quarter of 2025.

Backed by strong plant operations and growing client partnerships, the company continues to expand its production capacity and innovation in biomanufacturing.

CEO John Rim highlighted the company’s achievements: “We had a strong start to the year, thanks to efficient operations across all plants and continued trust from our clients.

“The opening of Plant 5 and our new ADC facility reflects our focus on meeting the diverse needs of our partners while delivering long-term value.”

Financial highlights

In Q1 2025, Samsung Biologics recorded consolidated revenue of KRW 1.3 trillion (US$ 914.1 million), up significantly from KRW 946.9 billion (US$ 665.8 million) in the same period last year.

The company also reported an operating profit of KRW 486.7 billion (US$ 342.2 million), more than double the KRW 221.3 billion (US$ 155.6 million) in Q1 2024.

This growth was driven by the smooth ramp-up of operations at Plant 4 and full capacity use in Plants 1–3, supported by favorable currency exchange rates.

On a standalone basis, revenue reached KRW 999.5 billion (US$ 702.8 million) with an operating profit of KRW 430.1 billion (US$ 302.4 million).

Strategic expansions

Samsung Biologics is moving fast to meet the rising global demand for biologics manufacturing.

Plant 5, which opened in April as scheduled, features advanced digital systems and cutting-edge technology to improve efficiency and quality. The company is also planning to build Plant 6, pending board approval.

In addition, the new antibody-drug conjugate (ADC) facility began operations earlier this year, reinforcing Samsung Biologics’ ability to support more complex biopharmaceutical products.

In January, Samsung Biologics secured a US$ 1.4 billion deal with a European pharma company, followed by more contract wins in April.

Supporting innovation and growth

Beyond manufacturing, Samsung Biologics is nurturing biotech innovation. Through its Samsung Life Science Fund, it recently invested in C2N Diagnostics, a U.S.-based firm working on early Alzheimer’s detection tools.

The company also signed a deal with LigaChem Biosciences for multiple ADC development projects. As part of its geographic growth, Samsung Biologics opened a new sales office in Japan to better serve its expanding global client base.

Additionally, Samsung Biologics continues to push for sustainable practices. It was rated a ‘Low Risk’ company by Sustainalytics and recognized for leadership in water security by the Carbon Disclosure Project.

The company is also part of the Sustainable Markets Initiative’s Health Systems Task Force, helping reduce carbon emissions in healthcare.